Teriparatide: Letter Responds to Postpartum Osteoporosis BMD Study

On September 25, 2026, a letter of response was published in Osteoporosis International concerning teriparatide. The letter responds to an observational study titled "Postpartum timing of teriparatide initiation and BMD response in pregnancy- and lactation-associated osteoporosis." Osteoporosis International is a journal established through cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. This new publication is a letter of response rather than the original research article. No findings, data, or conclusions from the letter's content were provided in this notice. The publication record identifies teriparatide as the compound discussed and situates the letter within the ongoing discussion of the original observational study. No details regarding the letter's specific arguments, critiques, or supporting evidence were included in the available information. Teriparatide remains an approved compound. Readers interested in the broader context of this discussion, including the original study's timing and BMD observations, should consult the full publication and its associated letter directly through the journal. For general background on teriparatide, including its approved status and other published research, readers can consult the compound overview page.